Mike Rizzo

Strasburg’s doctor: there are no studies supporting the Nats decision to shut him down

104 Comments

UPDATE II:  Yocum walks it back. Now he says he did talk to the Nats. Oy.

UPDATE: Boras says, nope, the Nats DID talk to Yocum. This is getting interesting.

12:33PM: All throughout the Strasburg Shutdown drama, we repeatedly heard how the doctors were all saying that it’s advisable to shut Strasburg down. That doctors were consulted and that the Nats’ plan was medically sound. Those of us who didn’t like the decision were told that we had to defer to the team and their cadre of medical experts because we, after all, are not doctors.

Only one problem: no one with the Nationals ever asked the guy who performed Strasburg’s surgery what he thought about it and, more significantly, the guy who performed the surgery tells the L.A. Times today that there are no studies supporting the proposition that shutting him down will protect him at all:

The doctor who performed elbow surgery on Stephen Strasburg said he did not tell the Washington Nationals to shut down their ace pitcher.

“I wasn’t asked,” Dr. Lewis Yocum told the Los Angeles Times … Yocum said that, had he been asked, he would not have been able to provide conclusive information about whether Strasburg’s long-term health would be best served by shutting him down.

“There’s no statistic as far as studies,” Yocum said.

Yocum further notes that it’s GM Mike Rizzo who came up with the 160 inning shutdown standard himself. That he imposed it in the case of Jordan Zimmermann, and that he’s doing the same with Strasburg without the aide of any medical directive.

Which, hey, that’s OK in and of itself. Zimmermann has worked out so far, so maybe Rizzo has stumbled upon a bold and effective new standard here. And it is his team and he can do what he wants and what he thinks is best for it.

But given the lack of studies on the matter, those people supporting the shutdown decision have to give up shaming those of us who don’t into silence with some notion that medical necessity or insight governed this decision.  End the erroneous appeals to medical authority — like Scott Boras has done repeatedly — and own up to the fact that it’s Mike Rizzo, not medical science, making this call.

Dee Gordon will return from his 80-game suspension on Thursday

WASHINGTON, DC - APRIL 10:  Dee Gordon #9 of the Miami Marlins runs the bases against the Washington Nationals at Nationals Park on April 10, 2016 in Washington, DC.  (Photo by Greg Fiume/Getty Images)
Greg Fiume/Getty Images
Leave a comment

At the end of April, Marlins second baseman Dee Gordon was handed an 80-game suspension by Major League Baseball after testing positive for exogenous testosterone and Clostebol, performance-enhancing drugs. Gordon says he took those substances unknowingly.

Gordon will return to the Marlins on Thursday, MLB.com’s Joe Frisaro reports. The club was 10-11 prior to Gordon’s suspension. Since then, the club has gone 43-35 and is now tied with the Mets for second place in the NL East, five games behind the Nationals. Impressively, the Marlins have collectively hit .272/.330/.408 in Gordon’s absence, which compares favorably to the league average .252/.320/.410 triple-slash line.

Gordon, who made the NL All-Star team in 2014 and ’15, was hitting .266/.289/.340 with three doubles, two triples, five RBI, 13 runs scored, and six stolen bases in 97 plate appearances. Derek Dietrich has handled second base in the meantime and has done an admirable job, batting .275/.366/.398 with 22 extra-base hits, 30 RBI, and 26 runs scored in 314 PA. Nevertheless, Gordon is likely to return to full-time duty at second base.

Report: Blue Jays to acquire Melvin Upton, Jr. from the Padres

SAN DIEGO, CALIFORNIA - JULY 2:  Melvin Upton Jr. #2 of the San Diego Padres hits a walk-off solo home run during the ninth inning of a baseball game against the New York Yankees at PETCO Park on July 2, 2016 in San Diego, California. The Padres won 2-1. (Photo by Denis Poroy/Getty Images)
Denis Poroy/Getty Images
3 Comments

Update (10:12 AM EDT): Jon Heyman of Today’s Knuckleball reports the Padres will receive pitcher Hansel Rodriguez from the Blue Jays. Rodriguez is rated as the Jays’ 18th-best prospect by MLB Pipeline. The Jays signed Rodriguez out of the Dominican Republic for $330,000 in February 2014. He’s spent the 2016 season with the Bluefield Blue Jays in rookie ball, compiling a 3.06 ERA with a 26/11 K/BB ratio in 32 1/3 innings over six starts.

*

The Padres and Blue Jays have agreed on a trade involving outfielder Melvin Upton, Ken Rosenthal of FOX Sports reported on Tuesday morning. The Jays will get Upton and the Padres will receive a prospect from Single-A. The financial details are not yet known, but Dennis Lin of the San Diego Union-Tribune says the Padres are expected to cover a significant portion of his remaining contract. The trade is likely to be finalized on Tuesday.

The two teams opened up a three-game series in Toronto on Monday, so Upton won’t have to go very far to join his new team. The Jays won 4-2 on Monday.

Upton, 31, has had another solid season for the Padres, batting .256/.304/.439 with 16 home runs, 45 RBI, 46 runs scored, and 20 stolen bases in 374 plate appearances. He’s owed the remainder of his $15.45 million salary for the 2016 season and $16.45 million next season, the final year of his five-year contract.

Upton will provide some outfield depth for the Jays, who currently only have Ezequiel Carrera as a full-time back-up outfielder behind Michael Saunders, Kevin Pillar, and Jose Bautista. Bautista was activated from the disabled list on Monday, so Upton could cover right field in the event that Bautista exacerbates his toe injury.

With Upton leaving San Diego, Alex Dickerson is likely to see full-time work in left field in the short term. Prospects Hunter Renfroe and Manuel Margot could be called up at some point this season as well.